Company profile
Hemostemix Inc
OTC: HMTXF · Healthcare · Biotechnology
Canadian filerHQ Calgary, ABReports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH 8DQ —GM —SS 59
v0.1 · 35/100 weight · pillars only
↑ workforce scale, disclosure history · ↓ Piotroski F, Altman-Z
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$3.4M
Employees
488
as of 2026-08-23
Market cap
$10.8M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2025
Net income-$3.4M-4.7M CAD2025
Operating income-$4.0M-5.6M CAD2025
Total assets$617.4k846.2k CAD2025
Liabilities$4.2M5.8M CAD2025
Equity-$3.6M-5.0M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Hemostemix Inc’s revenue?
Hemostemix Inc booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Izotropic Corporation——United Health Products, Inc.26DQuoin Pharmaceuticals, Ltd.37DIntegrated Cannabis Solutions, Inc.——Theriva Biologics, Inc.39DLunai Bioworks Inc.20DKey facts
CEOThomas A. Smeenk
SectorHealthcare
IndustryBiotechnology
HeadquartersCalgary, AB
ExchangeOTC: HMTXF
Employees488
IPO date2016-01-07
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.